Chugai Pharmaceutical
Chugai Pharmaceutical is a research and development-oriented pharmaceutical company with a focus on innovative drugs, especially biopharmaceuticals. In collaboration with Roche, it aims to generate continuous innovation to provide patients with advanced medical solutions. The company emphasizes patient-centric healthcare, sustainability, open innovation, and digital transformation as key drivers of its growth and societal contribution.
Industries
Nr. of Employees
Very Large (1000+)
Chugai Pharmaceutical
1-1, Kanda Surugadai, Chiyoda-ku, Tokyo 101-8426, Japan
Patents
Deprotection method and resin removal method in solid-phase reaction for peptide compound or amide compound, and method for producing peptide compound
US-12331072-B2
View Details
Deprotection method and resin removal method in solid-phase reaction for peptide compound or amide compound, and method for producing peptide compound
US-12331072-B2
View DetailsProducts
Next‑generation biologics drug substance manufacturing facility
A biologics drug substance manufacturing facility designed to support large‑scale production with emphasis on safety, speed, and sustainability.
Integrated R&D discovery platforms
Platforms supporting antibody, mid‑size molecule (cyclic peptide), and small‑molecule discovery to generate differentiated therapeutic candidates.
Next‑generation biologics drug substance manufacturing facility
A biologics drug substance manufacturing facility designed to support large‑scale production with emphasis on safety, speed, and sustainability.
Integrated R&D discovery platforms
Platforms supporting antibody, mid‑size molecule (cyclic peptide), and small‑molecule discovery to generate differentiated therapeutic candidates.
Services
Collaborative programs to co‑develop drug candidates and share discovery platforms with academic institutions, startups, and external research organizations.
Research collaborations and internal initiatives applying AI, generative AI, real‑world data, and digital biomarkers to improve drug discovery and clinical development processes.
On‑site science education facility offering experimental classes and programs for elementary to high school students to increase interest in biology and biotechnology.
Events, workshops, and advisory activities to share digital strategy, showcase digital solutions, and engage internal and external stakeholders in digital initiatives.
Collaborative programs to co‑develop drug candidates and share discovery platforms with academic institutions, startups, and external research organizations.
Research collaborations and internal initiatives applying AI, generative AI, real‑world data, and digital biomarkers to improve drug discovery and clinical development processes.
On‑site science education facility offering experimental classes and programs for elementary to high school students to increase interest in biology and biotechnology.
Events, workshops, and advisory activities to share digital strategy, showcase digital solutions, and engage internal and external stakeholders in digital initiatives.
Expertise Areas
- Antibody engineering
- Mid‑size molecule discovery (cyclic peptides)
- Small‑molecule drug discovery
- Bioprocess development and biologics manufacturing
Key Technologies
- Antibody engineering
- Bispecific antibody formats
- Conditionally activated antibody formats
- Cyclic peptide technologies
News & Updates
Celebrating 100 years of innovation and contribution to society since its founding in 1925.
Roche announced new safety information for Elevidys for non-ambulatory Duchenne Muscular Dystrophy.
Chugai received approval for Vabysmo for additional indication of angioid streaks, a cause of vision loss.
A report on the event with more than 3,000 attendees, showcasing the company's latest innovations and research activities.
Chugai promotes digital transformations in pharmaceuticals to achieve its growth strategy Top I 2030.
Share of Therapeutic Antibody Sales in Japan
No.1 in Japan.
Celebrating 100 years of innovation and contribution to society since its founding in 1925.
Roche announced new safety information for Elevidys for non-ambulatory Duchenne Muscular Dystrophy.
Chugai received approval for Vabysmo for additional indication of angioid streaks, a cause of vision loss.
A report on the event with more than 3,000 attendees, showcasing the company's latest innovations and research activities.
Chugai promotes digital transformations in pharmaceuticals to achieve its growth strategy Top I 2030.
Share of Therapeutic Antibody Sales in Japan
No.1 in Japan.